VivoSeq
Cardiovascular

Cardiovascular Events

0

Pipeline Programs↗

14

Active Trials↗

11

Companies Involved↗

Cardiovascular Events is an early-stage landscape with 0 programs across 11 companies. The most active players are Amgen, Eli Lilly, GSK.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalS

Sumitomo Pharma (Suzhou) Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

43

clinical trials

Completed22 · 51%
Recruiting6 · 14%
Unknown status4 · 9%
Active, not recruiting4 · 9%
Not yet recruiting3 · 7%
Withdrawn2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

43 trials

PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT05457582·1,212 enrolled
Identification of New Biomarkers for the Prediction of Cardiovascular Events
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT04809506·1,500 enrolled
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
Recruiting·CCurrax Pharmaceuticals·Phase 4·NCT06098079·8,600 enrolled
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Recruiting·PPoznan University of Medical Sciences·Phase 3·NCT05943821·1,116 enrolled
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
Recruiting·—·Phase 3·NCT07052799·2,514 enrolled
A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events
Recruiting·CCellcolabs Clinical LTD.·Phase 1/2·NCT06087848·100 enrolled
ASCEND: A Study of Cardiovascular Events iN Diabetes
Active, not recruiting·UUniversity of Oxford·Phase 4·NCT00135226·15,480 enrolled
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT06292013·17,300 enrolled
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Active, not recruiting·Amgen logoAmgen·Phase 3·NCT05581303·7,297 enrolled
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Active, not recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07185776·203 enrolled
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Not yet recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT07474649·103 enrolled
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Not yet recruiting·Amgen logoAmgen·Phase 3·NCT07293260·406 enrolled
PERLHS: How Institutional Guidelines for Urgent Inpatient Surgeries Affect Intensity of Perioperative Cardiovascular Testing: A PrePost Study
Not yet recruiting·JJohns Hopkins University·Preclinical·NCT07692503·3,000 enrolled
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population
Enrolling by invitation·—·N/A·NCT05462262·2,900 enrolled
UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events
Completed·IImperial College London·Phase 3·NCT01057537·2,004 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)